Effect of the SGLT2 Inhibitor Dapagliflozin on Potassium Levels in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis

por Yavin, Yshai, Mansfield, Traci A., Ptaszynska, Agata, Johnsson, Kristina, Parikh, Shamik, Johnsson, Eva
Publicado 2016

Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies

por Fioretto, Paola, Mansfield, Traci A., Ptaszynska, Agata, Yavin, Yshai, Johnsson, Eva, Parikh, Shamik
Publicado 2016

Assessing Bladder Cancer Risk in Type 2 Diabetes Clinical Trials: the Dapagliflozin Drug Development Program as a ‘Case Study’

por Ptaszynska, Agata, Cohen, Samuel M., Messing, Edward M., Reilly, Timothy P., Johnsson, Eva, Johnsson, Kristina
Publicado 2015